BCLI READ THE FULL BCLI RESEARCH REPORT Business Update Update on Planned Phase 3b Trial of NurOwn® in ALS On December 30, 2024, BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) conducted an investor ...

An NDA has been accepted by the FDA for the combination of avutometinib and defactinib in KRAS-mutated recurrent low-grade ...

Norgine today announced that it completed its marketing authorisation application filing to European Medicines Agency (EMA) for eflornithine in high-risk neuroblastoma (HRNB). This follows the ...

The country holds nearly half of the world’s known deposits of a metal critical to the energy transition, but digging and ...

Cell therapies have suffered from hyped-up expectations, clinical setbacks and high costs. But maybe, just maybe, Arovella is ...

According to Future Market Insights (FMI), global astaxanthin sales are estimated to be worth USD 273.2 million in 2024. The ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Drivers, business owners and residents expressed mixed feelings after the first morning rush hour under New York City’s ...

ST’s foreign bureaus outline how these power players will approach the new year. Read more at straitstimes.com.

The story of SA’s deindustrialisation over the last 50 years is alarming, and reversing it should be a priority for our ...

Dyadic management will attend the J.P. Morgan Healthcare Conference in San Francisco, January 13–16, 2025. If you would like to schedule a meeting, please contact Dyadic at [email protected]. About ...

Researchers MSK and their collaborators at Mount Sinai have developed an artificial intelligence-based model to predict who ...